Synlogic, Inc. (SYBX): Price and Financial Metrics


Synlogic, Inc. (SYBX): $2.42

-0.17 (-6.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SYBX POWR Grades


  • Sentiment is the dimension where SYBX ranks best; there it ranks ahead of 89.53% of US stocks.
  • The strongest trend for SYBX is in Growth, which has been heading up over the past 52 weeks.
  • SYBX ranks lowest in Momentum; there it ranks in the 8th percentile.

SYBX Stock Summary

  • SYBX's price/sales ratio is 158.38; that's higher than the P/S ratio of 97.65% of US stocks.
  • Revenue growth over the past 12 months for Synlogic Inc comes in at -34.57%, a number that bests merely 6.11% of the US stocks we're tracking.
  • Synlogic Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -53.28%, greater than the shareholder yield of just 5.88% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Synlogic Inc, a group of peers worth examining would be VBLT, ALT, BBI, AYLA, and AGTC.
  • SYBX's SEC filings can be seen here. And to visit Synlogic Inc's official web site, go to www.synlogictx.com.

SYBX Valuation Summary

  • SYBX's price/sales ratio is 570.7; this is 4928.19% higher than that of the median Healthcare stock.
  • SYBX's price/sales ratio has moved NA NA over the prior 72 months.
  • SYBX's price/sales ratio has moved NA NA over the prior 72 months.

Below are key valuation metrics over time for SYBX.

Stock Date P/S P/B P/E EV/EBIT
SYBX 2021-08-31 570.7 1.1 -2.5 -2.3
SYBX 2021-08-30 576.8 1.1 -2.5 -2.3
SYBX 2021-08-27 549.2 1.1 -2.4 -2.2
SYBX 2021-08-26 562.2 1.1 -2.4 -2.3
SYBX 2021-08-25 570.7 1.1 -2.5 -2.3
SYBX 2021-08-24 559.8 1.1 -2.4 -2.3

SYBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SYBX has a Quality Grade of C, ranking ahead of 35.88% of graded US stocks.
  • SYBX's asset turnover comes in at 0.002 -- ranking 425th of 681 Pharmaceutical Products stocks.
  • RMTI, FATE, and FBRX are the stocks whose asset turnover ratios are most correlated with SYBX.

The table below shows SYBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.437
2021-03-31 0.003 1 -0.440
2020-12-31 0.004 1 -0.412
2020-09-30 0.011 1 -0.366
2020-06-30 0.012 1 -0.338
2020-03-31 0.010 1 -0.291

SYBX Price Target

For more insight on analysts targets of SYBX, see our SYBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.42 (Moderate Buy)

SYBX Stock Price Chart Interactive Chart >

Price chart for SYBX

SYBX Price/Volume Stats

Current price $2.42 52-week high $5.11
Prev. close $2.59 52-week low $2.07
Day low $2.42 Volume 199,648
Day high $2.73 Avg. volume 596,359
50-day MA $2.78 Dividend yield N/A
200-day MA $3.32 Market Cap 168.70M

Synlogic, Inc. (SYBX) Company Bio


Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SYBX Latest News Stream


Event/Time News Detail
Loading, please wait...

SYBX Latest Social Stream


Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about Synlogic Inc that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic (NASDAQ:SYBX) shareholders have endured a 69% loss from investing in the stock three years ago

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

Yahoo | November 12, 2021

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2021

Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data from the company's clinical development program for phenylketonuria (PKU) during the 14th International Congress of Inborn Errors of Metabolism Meeting being held in Sydney, Australia November 21-24, 2021.

Yahoo | November 10, 2021

Synlogic Reports Third Quarter Financial Results and Provides Business Update

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended September 30, 2021 and provided an update on clinical programs.

Yahoo | November 10, 2021

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the nomination of SYNB1353, an investigational Synthetic BioticTM medicine for the treatment of homocystinuria (HCU). SYNB1353 is the first product developed through a research collaboration between Synlogic and Ginkgo and the first investigational medicine developed o

Yahoo | November 9, 2021

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo -5.47%
3-mo -9.70%
6-mo -32.40%
1-year -3.20%
3-year -71.56%
5-year -77.55%
YTD 12.04%
2020 -16.28%
2019 -63.20%
2018 -27.73%
2017 -23.02%
2016 -71.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.851 seconds.